Location History:
- Winston-Salem, NC (US) (2012)
- Lewisville, NC (US) (2014 - 2017)
Company Filing History:
Years Active: 2012-2017
Title: Innovations and Contributions of Inventor Srinivasa V Murthy
Introduction
Srinivasa V Murthy is a notable inventor based in Lewisville, NC (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target neuronal nicotinic acetylcholine receptors. With a total of 3 patents to his name, his work has the potential to impact the treatment of various central nervous system disorders.
Latest Patents
One of his latest patents involves nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes. This invention discloses compounds and pharmaceutical compositions that exhibit selectivity for neuronal nicotinic receptors of the α4β2 subtype in the central nervous system. These compounds can alter the number of nicotinic cholinergic receptors in the brain, exhibit neuroprotective effects, and do not result in significant adverse side effects. Another patent focuses on 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands. This invention relates to compounds that bind to and modulate the activity of these receptors, offering potential treatments for various CNS disorders.
Career Highlights
Throughout his career, Srinivasa V Murthy has worked with several companies, including Targacept, Inc. and Attenua, Inc. His expertise in the field has allowed him to contribute to innovative research and development projects that aim to improve therapeutic options for patients.
Collaborations
Srinivasa has collaborated with notable colleagues such as Anatoly A Mazurov and Yunde Xiao. These collaborations have further enriched his research and development efforts in the pharmaceutical industry.
Conclusion
Srinivasa V Murthy's contributions to the field of pharmaceutical sciences through his innovative patents and collaborations highlight his commitment to advancing medical treatments. His work continues to pave the way for new therapeutic options for central nervous system disorders.